###begin article-title 0
Fatty Acid Synthase Inhibitors Modulate Energy Balance via Mammalian Target of Rapamycin Complex 1 Signaling in the Central Nervous System
###end article-title 0
###begin p 1
###xml 39 58 39 58 <email xmlns:xlink="http://www.w3.org/1999/xlink">randy.seeley@uc.edu</email>
Corresponding author: Randy J. Seeley, randy.seeley@uc.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Evidence links the hypothalamic fatty acid synthase (FAS) pathway to the regulation of food intake and body weight. This includes pharmacological inhibitors that potently reduce feeding and body weight. The mammalian target of rapamycin (mTOR) is an intracellular fuel sensor whose activity in the hypothalamus is also linked to the regulation of energy balance. The purpose of these experiments was to determine whether hypothalamic mTOR complex 1 (mTORC1) signaling is involved in mediating the effects of FAS inhibitors.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 379 382 379 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 224 228 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 288 292 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 345 349 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 476 480 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
RESEARCH DESIGN AND METHODS-We measured the hypothalamic phosphorylation of two downstream targets of mTORC1, S6 kinase 1 (S6K1) and S6 ribosomal protein (S6), after administration of the FAS inhibitors C75 and cerulenin in rats. We evaluated food intake in response to FAS inhibitors in rats pretreated with the mTOR inhibitor rapamycin and in mice lacking functional S6K1 (S6K1-/-). Food intake and phosphorylation of S6K1 and S6 were also determined after C75 injection in rats maintained on a ketogenic diet.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 143 146 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 127 131 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 147 151 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 250 254 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
RESULTS-C75 and cerulenin increased phosphorylation of S6K1 and S6, and their anorexic action was reduced in rapamycin-treated rats and in S6K1-/- mice. Consistent with our previous findings, C75 was ineffective at reducing caloric intake in ketotic rats. Under ketosis, C75 was also less efficient at stimulating mTORC1 signaling.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-These findings collectively indicate an important interaction between the FAS and mTORC1 pathways in the central nervous system for regulating energy balance, possibly via modulation of neuronal glucose utilization.
###end p 6
###begin p 7
Published ahead of print at  on 5 September 2008.
###end p 7
###begin p 8
K.P. and D.C. contributed equally to this study.
###end p 8
###begin p 9
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
Energy balance is achieved when caloric intake is matched to expenditure. A complex neuroendocrine system underlies this process and regulates energy homeostasis in mammals. In addition to sensing hormonal signals of stored fuels, such as leptin (1), specific populations of neurons in the central nervous system (CNS), and particularly within the hypothalamus, have the ability to sense locally available nutrients, including glucose (2), fatty acids (3), and amino acids (4,5).
###end p 10
###begin p 11
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 785 786 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
Recent evidence has highlighted the role of intracellular fuel sensing in the regulation of energy balance (6). In particular, the biochemical pathway underlying fatty acid metabolism has been involved in the regulation of both feeding and glucose homeostasis (6-10). Fatty acid synthase (FAS) catalyzes the condensation of malonyl-CoA and acetyl-CoA to generate long-chain fatty acids (LCFAs). Acetyl-CoA carboxylase (ACC) and FAS are expressed in the hypothalamus (7), where malonyl-CoA (11) and LCFA-CoA levels (8) decrease during fasting and increase after refeeding. Studies using FAS inhibitors and other pharmacological or genetic tools that modify the activity of different enzymes regulating fatty acid metabolism support a role for this pathway in the regulation of feeding (9,12-15).
###end p 11
###begin p 12
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
Peripheral administration of the natural FAS inhibitor cerulenin (2,3-epoxy-4-oxo-6-dodecadienoylamide) or the synthetic inhibitor C75 (trans-4-carboxy-5-octyl-3-methylenebutyrolactone) causes profound dose-dependent anorexia and weight loss in several rodent models (12,13,15,16). Reduced food intake is also observed with central administration of much lower doses of C75, suggesting that the brain is the key site of action (12). Increased hypothalamic malonyl-CoA is necessary for the anorexic and weight-reducing effects of FAS inhibitors (9,15,17). Interestingly, the ability of leptin to reduce food intake depends on increased hypothalamic malonyl-CoA (8) and possibly palmitoyl-CoA (18), which are achieved through the concomitant inhibition of AMP-activated protein kinase (AMPK) and activation of ACC (18). Therefore, the hypothalamic fatty acid synthesis pathway appears to process different fuel signals and convert them into efferent outputs that prevent further consumption of nutrients.
###end p 12
###begin p 13
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 919 920 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that controls critical aspects of cell growth (19). mTOR is a component of at least two multiprotein complexes: mTOR complex 1 (mTORC1), which includes raptor, and mTOR complex 2 (mTORC2), which includes rictor. Whereas mTORC2 regulates phosphorylation of Akt, mTORC1 modulates the activity of S6 kinase 1 (S6K1) and 4E binding protein 1 (20). Notably, the phosphorylation of S6K1 at Thr 389 is one of the markers commonly used to evaluate mTORC1 activity in vivo (21). Insulin, IGF, amino acids, and glucose all activate intracellular cascades that lead to activation of mTORC1 (22). We reported that the anorexic action of central leptin and leucine are both dependent on the activation of mTORC1 signaling in the hypothalamus (4). Given the ability of mTORC1 to sense and integrate fuel signals, and the role it plays in controlling food intake (4), we hypothesized that mTORC1 signaling is involved in monitoring the biochemical changes induced by the modulation of hypothalamic fatty acid metabolism.
###end p 13
###begin title 14
RESEARCH DESIGN AND METHODS
###end title 14
###begin title 15
Animals.
###end title 15
###begin p 16
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 22 26 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 36 40 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 90 94 <span type="species:ncbi:10090|species:ncbi:10095">Mice</span>
###xml 440 444 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
Adult male Long-Evans rats, S6K1-/- mice, and their wild-type littermates (23) were used. Mice were 8-11 weeks old in the cerulenin study and 7 months old in the C75 study. All animals were housed individually and maintained on a 12:12-h light-dark cycle, standard lab chow (Harlan-Teklad, Indianapolis, IN), and water. All animal procedures were approved by the institutional animal care and use committee of the University of Cincinnati. Rats were implanted with intracerebroventricular (icv) cannulas as previously described (24) and allowed to recover for a minimum of 7 days. Cannula placement was confirmed by consuming >5 ml water after 10 ng angiotensin II icv.
###end p 16
###begin title 17
Drugs.
###end title 17
###begin p 18
C75 (Calbiochem; EMD Bioscience, La Jolla, CA) was dissolved in RPMI (Gibco, Carlsbad, CA). Cerulenin (Sigma-Aldrich, St. Louis, MO) was first dissolved in DMSO followed by RPMI, to a final concentration of 25% DMSO. Rapamycin (Calbiochem, EMD Bioscience) was dissolved in DMSO. All vehicles served as controls.
###end p 18
###begin title 19
Ketogenic diet.
###end title 19
###begin p 20
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 0 4 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
Rats were placed on a ketogenic diet (80.7% lipid, 14.3% protein, and 5% carbohydrate calories; Dyet 100959; Dyets, Bethlehem, PA) for 4 weeks (13). Blood beta-hydroxybutyrate concentration was measured using the KetoSite test (Stanbio Laboratory, Boerne, TX).
###end p 20
###begin title 21
Leucine measurement.
###end title 21
###begin p 22
Plasma samples were deproteinized with sulfosalicylic acid and analyzed using an automated Hitachi L8800 Amino Acid Analyzer.
###end p 22
###begin title 23
Western blot.
###end title 23
###begin p 24
###xml 604 605 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 979 990 <span type="species:ncbi:3704">horseradish</span>
###xml 1003 1007 <span type="species:ncbi:9925">goat</span>
###xml 1013 1019 <span type="species:ncbi:9986">rabbit</span>
###xml 1545 1551 <span type="species:ncbi:9986">rabbit</span>
###xml 1604 1610 <span type="species:ncbi:9986">rabbit</span>
A wedge of mediobasal hypothalamus was dissected using as landmarks the mammillary bodies caudally, the optic chiasm rostrally, the optic tract laterally, and the apex of the third ventricle. Tissues were homogenized in radioimmunoprecipitation assay buffer with addition of phosphatase and protease inhibitors (Santa Cruz Biotechnology). Samples (70 mug) were loaded on either a 9-13% (experiment 1) or a 10% (experiments 3 and 4) SDS-polyacrylamide gel (Bio-Rad). Proteins were separated by electrophoresis and transferred to nitrocellulose membranes. Membranes were processed as previously described (4) before overnight incubation at 4degreesC with either phosphorylated S6K1 (pS6K1) at Thr 389 (1:500; Cell Signaling Technology, Beverly, MA) or phosphorylated S6 (pS6) at Ser 240/244 (1:500; Cell Signaling Technology). After washing in Tris-buffered saline with Tween (TBST), the membranes were incubated for 1 h at room temperature with secondary antibody conjugated with horseradish peroxidase (goat anti-rabbit; 1:2,000; Cell Signaling Technology). After washes in TBST, immunopositive bands were visualized by chemiluminescence (Lumiglo reagent and peroxide kit; Cell Signaling Technology) using exposure to radiographic films (Denville Scientific, South Plainfield, NJ). After protein detection, membranes were stripped for 15 min at 55degreesC with a solution containing 62.5 mmol/l Tris-HCl, 100 mmol/l 2-mercaptoethanol, and 2% SDS before 2-h blocking in TBST with 5% skim milk powder at room temperature and reblotted with either rabbit anti-p70-S6K1 (Cell Signaling Technology, 1:250) or rabbit anti-S6 (1:500; Cell Signaling Technology). Density was determined by National Institutes of Health program Scion image.
###end p 24
###begin title 25
Experimental design
###end title 25
###begin title 26
Experiment 1: effect of C75 on hypothalamic mTORC1 signaling.
###end title 26
###begin p 27
###xml 22 26 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
One hour before dark, rats were injected with C75 (30 mug in 2 mul icv) or vehicle and killed 30 min, 1 h, or 6 h later. Brains were removed, immediately frozen in isopentane, and stored at -80degreesC until Western blot analysis.
###end p 27
###begin title 28
###xml 61 65 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Experiment 2: effect of rapamycin on C75-induced anorexia in rats.
###end title 28
###begin p 29
###xml 253 255 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 25 29 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Three hours before dark, rats were injected with either DMSO or rapamycin (25 mug in 1 mul icv) followed by RPMI or C75 (50 mug in 3 mul icv) 2 h later. Food was weighed at 1, 4, 8, and 24 h. Body weight was measured after 24 h. As previously reported (18), we found that some CNS active compounds, including leptin and C75, are less effective when animals are pretreated with DMSO. In these conditions, the dose of C75 had to be raised to 50 mug to reach the same degree of anorexia as that observed with 30 mug.
###end p 29
###begin title 30
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 63 67 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Experiment 3: anorexic actions of C75 and cerulenin in S6K1-/- mice.
###end title 30
###begin p 31
###xml 22 26 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
One hour before dark, mice were injected intraperitoneally with C75 (20 mg/kg body wt), cerulenin (160 mg/kg body wt), or their respective vehicles; and food was weighed at 1, 4, 10, and 24 h. Body weight was measured at 24 h. The experiments used a within-subjects design with treatment order counterbalanced and 1 week between each treatment.
###end p 31
###begin title 32
Experiment 4: effect of cerulenin on hypothalamic mTORC1 signaling.
###end title 32
###begin p 33
###xml 0 4 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
Rats were injected intracerebroventricularly with cerulenin (90 mug in 2 mul) and killed as in experiment 1.
###end p 33
###begin title 34
Experiment 5: effect of the ketogenic diet on C75-induced anorexia.
###end title 34
###begin p 35
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 0 4 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
###xml 62 66 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 177 181 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 290 294 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 358 362 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Rats were divided into two groups (saccharin or sucrose). All rats had ad libitum access to a ketogenic diet, water, and a sucrose or saccharin solution (13). Four weeks later, rats were fasted for 24 h, and ketosis was confirmed by a significant elevation of blood beta-hydroxybutyrate in rats that had access to saccharin versus sucrose. Three days later, rats were fasted overnight and given RPMI or C75 (30 mug in 2 mul icv) 1 h before lights off. Food and bottles of sucrose or saccharin were returned and weighed at 4 and 24 h.
###end p 35
###begin title 36
Experiment 6: effect of the ketogenic diet on C75-induced changes in pS6K1 and pS6.
###end title 36
###begin p 37
###xml 177 181 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
The protocol was the same as for experiment 5, except that food, sucrose, and saccharin were not returned after the injection to avoid any confounding effect of caloric intake. Rats were killed 1 h after receiving either C75 or RPMI, and brains were collected for Western blot, as described above.
###end p 37
###begin title 38
Statistical analyses.
###end title 38
###begin p 39
###xml 293 294 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 357 358 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
All values are expressed as means +/- SE. Data were analyzed by two-way ANOVA for multiple group designs and one-way repeated measures ANOVA for within-subjects design, followed by Fisher's least significant differences post hoc tests. Designs with only two groups were assessed with unpaired t tests. Experiment-wise significance was two-tailed and set at P < 0.05.
###end p 39
###begin title 40
RESULTS
###end title 40
###begin title 41
C75 increases hypothalamic mTORC1 signaling.
###end title 41
###begin p 42
###xml 127 128 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 211 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 300 301 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 306 307 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 294 307 286 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic> and <italic>B</italic></xref>
###xml 385 386 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 391 392 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 379 392 371 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic> and <italic>D</italic></xref>
C75 had no effect on the phosphorylation of either S6K1 (pS6K1/S6K1: RPMI, 100.00 +/- 8.36% vs. C75, 86.49 +/- 11.68% of RPMI; P = 0.365) or S6 (pS6/S6: RPMI, 100 +/- 18.36% vs. C75, 105.59 +/- 14.45% of RPMI; P = 0.816) 30 min after injection. At 1 h, C75 increased the phosphorylation of S6 (Fig. 1A and B), and at 6 h, this was accompanied by a significant elevation of pS6K (Fig. 1C and D).
###end p 42
###begin title 43
mTORC1 signaling mediates the anorexic action of C75.
###end title 43
###begin p 44
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 428 435 428 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 46)</sub>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 516 517 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 583 584 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 589 590 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 577 590 577 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 661 662 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 662 669 662 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 46)</sub>
###xml 678 679 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 748 749 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 758 765 758 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 926 927 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1008 1009 1008 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1024 1025 1024 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1018 1025 1018 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 1072 1073 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1078 1079 1078 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1066 1079 1066 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 1175 1176 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1176 1183 1176 1183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 46)</sub>
###xml 1192 1193 1192 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1241 1242 1241 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1242 1249 1242 1249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 46)</sub>
###xml 1258 1259 1258 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1311 1312 1311 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1312 1319 1312 1319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 46)</sub>
###xml 1329 1330 1329 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1401 1402 1401 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1417 1418 1417 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1411 1418 1411 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1494 1495 1494 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1495 1502 1495 1502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 46)</sub>
###xml 1511 1512 1511 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 142 146 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
We have found that refeeding activates hypothalamic mTORC1 signaling, whereas pharmacological inhibition of CNS mTOR increases food intake in rats (4). Given that C75 increased hypothalamic pS6K1 and pS6, we evaluated whether C75-induced anorexia depends on activation of the mTORC1 signaling by using the potent and selective mTOR inhibitor rapamycin (25). There was a main effect of the second drug treatment on food intake (F(1, 46) = 29.03, P < 0.001). Within the 1st h after injection, C75 reduced food intake (P < 0.01), and this effect persisted for the following 24 h (Fig. 2A and B). There was a main effect of the first drug treatment on food intake (F(1, 46) = 5.53, P < 0.05). The dose of rapamycin used decreased feeding in the 1st h (P < 0.01; Fig. 2A), which was surprising given that we had never observed an effect of this dose in any prior studies (Appendix 1, which is available in an online appendix at ) (4). Nonetheless, pretreatment with rapamycin blocked C75-induced anorexia by 4 h (P < 0.05; Fig. 2A), and the inhibition persisted at 24 h (Fig. 2A and B). There was an interaction between the first and second drug treatments on food intake at 8 h (F(1, 46) = 4.16, P < 0.05). There were main effects of the first (F(1, 46) = 7.63, P < 0.01) and second drug treatments on body weight (F(1, 46) = 10.57, P < 0.01). Rapamycin prevented the weight loss effect of C75 over 24 h (P < 0.05; Fig. 2C). The interaction between the two drug treatments approached significance (F(1, 46) = 4.03, P = 0.05).
###end p 44
###begin p 45
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 113 116 113 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 183 186 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 266 270 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 270 273 268 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 293 294 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 421 422 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 415 422 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 497 501 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 501 504 495 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 542 543 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 598 599 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 599 606 591 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 10)</sub>
###xml 616 617 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 700 701 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 716 717 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 710 717 702 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 776 777 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 792 793 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 798 799 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 786 799 778 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic> and <italic>E</italic></xref>
###xml 827 831 819 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 831 834 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 874 875 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 890 891 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 884 891 876 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 936 937 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 937 944 929 936 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 10)</sub>
###xml 953 954 945 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1047 1048 1039 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1048 1055 1040 1047 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 10)</sub>
###xml 1064 1065 1056 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1181 1185 1171 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 1185 1188 1175 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1227 1228 1215 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1290 1291 1278 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1291 1298 1279 1286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 10)</sub>
###xml 1308 1309 1296 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1371 1375 1359 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 1375 1378 1363 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1380 1381 1368 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1397 1398 1385 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1391 1398 1379 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>F</italic></xref>
###xml 187 191 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 230 234 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 770 774 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 835 839 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1531 1535 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1540 1544 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
To assess the role of the mTORC1 pathway in mediating the potent anorexic effects of FAS inhibitors, we used S6K1-/- and their wild-type littermates. As previously reported (26), S6K1-/- mice had lower body weights than wild-type mice (wild type, 29.36 +/- 1.30 vs. S6K1-/-, 25.60 +/- 0.78 g; P < 0.05). However, their cumulative 24-h food intake was similar to that of controls, whether expressed as total intake (Fig. 2E) or intake per kilogram body weight (wild type/RPMI, 139.68 +/- 26.99 vs. S6K1-/-/RPMI, 156.38 +/- 15.52 g/kg body wt; P = 0.603). There was a main effect of drug on feeding (F(1, 10) = 30.07, P < 0.001). C75 significantly decreased food intake in both genotypes in the 1st h (P < 0.01; Fig. 2D). The suppression lasted at least 24 h in wild-type mice (P < 0.01; Fig. 2D and E). However, the response of S6K1-/- mice was significantly blunted at 4 h (P < 0.05; Fig. 2D), as revealed by a main effect of genotype (F(1, 10) = 5.69, P < 0.05). There was a significant interaction between drug and genotype between 10 and 24 h (F(1, 10) = 7.06, P < 0.05), even when expressed as grams per kilogram body weight (interval 10-24 h: wild type/C75, 8.95 +/- 5.72 vs. S6K1-/-/C75, 29.34 +/- 6.21 g/kg body weight; P < 0.05). We also found a main effect of drug on weight loss (F(1, 10) = 49.28, P < 0.001), and there was a trend for C75 to be less potent in S6K1-/- (P = 0.077; Fig. 2F). Thus, the pharmacological and genetic data imply that intact mTORC1 signaling is necessary for the full anorexic effect of C75 in rats and mice at time points beyond 4 h.
###end p 45
###begin title 46
Cerulenin activates hypothalamic mTORC1 signaling, and this effect is required for its anorexic action.
###end title 46
###begin p 47
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 254 255 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 242 255 242 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic> and <italic>B</italic></xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 504 505 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 505 512 505 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 13)</sub>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 628 632 628 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 632 635 632 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 696 700 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 700 703 700 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 721 722 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 715 722 715 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 783 784 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 784 791 784 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 13)</sub>
###xml 801 802 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 842 843 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 836 843 836 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>E</italic></xref>
###xml 964 965 964 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 965 972 965 972 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 13)</sub>
###xml 982 983 982 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 998 999 998 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 992 999 992 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 1037 1038 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1038 1045 1038 1045 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1, 13)</sub>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1071 1072 1071 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1065 1072 1065 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>E</italic></xref>
Because no pharmacological agent is specific to a single pathway, we further tested our hypothesis by using a second FAS inhibitor. Cerulenin activated mTORC1 signaling in a pattern similar to that of C75 by phosphorylating both S6K1 and S6 (Fig. 3A and B). Moreover, cerulenin also required intact mTORC1 signaling to cause anorexia. Consistent with previous reports (15,16), cerulenin decreased food consumption, as revealed by a main effect of drug that started 1 h after injection in both genotypes (F(1, 13) = 33.61, P < 0.001). This effect persisted in the following 4- to 24-h period in wild type (P < 0.001), but not in S6K1-/-, whose food consumption was similar to that of VEH-injected S6K1-/- after 4 h (Fig. 3C). There was also a main effect of drug on 24-h weight loss (F(1, 13) = 22.00, P < 0.001), but only in wild type (Fig. 3E). There was a trend for an interaction between genotype and drug on feeding at 4 h, which reached significance at 24 h (F(1, 13) = 15.84, P < 0.01; Fig. 3D) and was also found for weight loss (F(1, 13) = 10.61, P < 0.01; Fig. 3E). The observation that two different FAS inhibitors modulate hypothalamic mTORC1 and require mTORC1 signaling for their anorexic action makes a strong case for a link between mTORC1 and FAS in the regulation of feeding.
###end p 47
###begin title 48
###xml 75 79 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
The actions of C75 on hypothalamic mTORC1 signaling are blunted in ketotic rats.
###end title 48
###begin p 49
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 444 445 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 461 462 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 455 462 452 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 520 521 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 521 527 518 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1,28)</sub>
###xml 537 538 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 560 561 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 561 567 558 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1,28)</sub>
###xml 576 577 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 708 709 705 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 882 883 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 876 883 873 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 964 965 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 981 982 978 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 975 982 972 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1143 1144 1140 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1144 1150 1141 1147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1,27)</sub>
###xml 1159 1160 1156 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1178 1179 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1179 1185 1176 1182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1,26)</sub>
###xml 1195 1196 1192 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1227 1228 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1228 1234 1225 1231 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1,26)</sub>
###xml 1243 1244 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1297 1298 1294 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1298 1304 1295 1301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(1,26)</sub>
###xml 1313 1314 1310 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1451 1452 1448 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1467 1468 1464 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1461 1468 1458 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 1516 1517 1513 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1558 1559 1555 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1574 1575 1571 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1568 1575 1565 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 397 401 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 653 657 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 819 823 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 937 941 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1068 1072 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1095 1099 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1425 1429 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1445 1449 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1510 1514 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
We had previously hypothesized that a key signal leading to C75-induced anorexia is derived, at least in part, from its ability to increase CNS glucose utilization, and we demonstrated that C75 does not reduce food intake under ketosis (13). Here, we explored the possibility that this is due to inability to modulate CNS mTORC1 signaling. Blood beta-hydroxybutyrate was significantly elevated in rats given access to saccharin versus sucrose (P < 0.001; Fig. 4A). There was a main effect of drug on food intake at 4 h (F(1,28) = 12.74, P < 0.01) and at 24 h (F(1,28) = 9.33, P < 0.01). Consistent with its effect on chow, C75 reduced caloric intake in rats whose ketosis was prevented by access to sucrose (P < 0.01), and this effect lasted for 24 h. However, the caloric-reducing effect of C75 was blunted in ketotic rats receiving saccharin at 4 (data not shown) and 24 h (Fig. 4B) and was nearly statistically different from that of rats in the sucrose group (P = 0.059; Fig. 4B). These effects were accompanied by reduced hypothalamic mTORC1 signaling in ketotic rats compared with sucrose rats. There was a main effect of drug on pS6K1 (F(1,27) = 5.56, P < 0.05) and pS6 (F(1,26) = 27.19; P < 0.001). The effect of diet (F(1,26) = 3.89, P = 0.059) and the interaction between drug and diet (F(1,26) = 3.92, P = 0.058) nearly reached statistical significance for pS6. C75 was less efficient at increasing pS6 in ketotic rats versus sucrose rats (P < 0.05; Fig. 4D), and it increased pS6K1 only in sucrose rats (P < 0.01) (sucrose-C75 vs. saccharin-C75, P < 0.05; Fig. 4C). Thus, the anorexic action of C75 appears to depend on the rate of neuronal glucose uptake and/or utilization. Moreover, this rate could also affect the ability of C75 to modulate mTORC1 signaling.
###end p 49
###begin p 50
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 632 633 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 626 633 626 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 109 113 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 318 322 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
Ketosis is known to induce profound metabolic changes (27), so we compared sucrose- versus saccharin-treated rats on the same gel. Ketosis had no significant effect on the basal phosphorylation of S6K1 but caused a nonsignificant increase in S6 phosphorylation (Appendix 2, which is available in the online appendix). Rats fed a ketogenic diet have increased leucine levels in the cerebral cortex (28). Given the important role of leucine in regulating mTOR (29,30), we determined whether the ketogenic diet changes plasma leucine levels. However, we did not find any difference in circulating leucine between the two groups (Fig. 4E).
###end p 50
###begin title 51
DISCUSSION
###end title 51
###begin p 52
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
Modulation of the FAS pathway represents a therapeutic strategy to produce weight loss and points to the important role of CNS metabolic pathways in regulating energy balance (6,31). Our previous work has demonstrated that activation of mTORC1 signaling in the hypothalamus reduces food intake (4). This led us to hypothesize that the ability of FAS inhibitors to modulate hypothalamic mTORC1 signaling is an important mechanism by which they cause anorexia.
###end p 52
###begin p 53
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
Here, we report that central administration of C75 or cerulenin increases phosphorylation of hypothalamic S6K1 and S6. Furthermore, the ability of these compounds to modulate feeding depended on the activation of CNS mTORC1 signaling. In fact, intracerebroventricular rapamycin dampened the ability of C75 to reduce both feeding and body weight (4). We were surprised to observe an effect of rapamycin to reduce feeding in the 1st h after injection, given that we had not seen an effect of this dose in several prior studies (Appendix 1) (4). Nonetheless, it is important to point out that this effect on food intake is short-lived, with no effect observed beyond 1 h. Importantly, rapamycin actually resulted in an increase in intake in the presence of C75, which is incompatible with a major effect of rapamycin to reduce food intake.
###end p 53
###begin p 54
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 437 440 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 697 701 697 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 701 704 701 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 220 224 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 349 353 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 441 445 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 705 709 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 760 764 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Although rapamycin is quite specific in its effect on mTORC1 signaling (4), pharmacological inhibitors can have drawbacks that limit the interpretation of experimental results. Hence, we further tested our hypothesis in mice lacking S6K1, a key component of the mTORC1 pathway. C75 or cerulenin reduced both food intake and body weight in wild-type mice, as reported before (17,32). However, this effect was significantly reduced in S6K1-/- mice. Interestingly, the data arising from both the pharmacological and genetic studies indicate that the activity of the mTORC1 pathway critically contributes to the anorexic effects of FAS inhibitors 4 h after drug injection. The time course observed in S6K1-/- mice is a remarkable match for the observation made in rats that activation of mTORC1 remains elevated 6 h after either C75 or cerulenin. Such data underscore the importance of the mTORC1 signaling as one component of a cascade that is essential to the anorexic effects of FAS inhibitors.
###end p 54
###begin p 55
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1956 1958 1956 1958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 555 559 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 801 805 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 905 909 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1057 1061 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
One proposed mechanism by which FAS inhibitors suppress food ingestion is by increasing CNS glucose utilization (13). Glucose metabolism is a biochemical index of nutrient status that plays a key role in the control of feeding. Quantitative and temporal changes in glucose concentration are closely monitored and integrated by specific subpopulations of "glucosensing" neurons in the CNS that are crucial to the regulation of feeding (6). A key finding to support the involvement of increased glucose use in mediating the effect of FAS inhibition is that rats on a very low carbohydrate diet, which forces them to produce ketone bodies that neurons use in preference to glucose (33), do not reduce their food intake in response to C75 (13). In accordance with those previous results, we observed that rats maintained on a ketogenic diet but given sucrose to prevent ketosis responded to C75. In contrast, rats maintained on the ketogenic diet but given saccharin did not significantly reduce their food intake after C75. C75 increased S6 phosphorylation in rats on the ketogenic diet supplemented with sucrose, but this effect is blunted in those on the same diet supplemented with saccharin. This effect is consistent with what has been observed under chow diet. It remains unknown how C75 increases the phosphorylation of S6K1 1 h after injection under a ketogenic diet supplemented with sucrose, whereas this phenomenon happens only at 6 h under a chow diet. This is an issue that we tested several times with multiple time points. In several studies, there was a strong trend for increased pS6K1 at 1 h, but this effect was not consistent across experiments, unlike the reliable effect to increase pS6. There could be a number of possibilities to explain why the time course of C75-induced phosphorylation of S6K1 differs between the two diets. The ketogenic diet induces a wide range of metabolic effects in addition to reducing glucose availability (27). These differences provide an important rationale for why we used the ketogenic diet supplemented with sucrose instead of a normal chow diet as the control for experiment 4. Nonetheless, these findings not only point to the permissive role played by neuronal glucose metabolism in the FAS inhibitors-induced anorexia, but they also highlight a mechanism through which the inhibition of FAS leads to the modulation of the mTORC1 signaling.
###end p 55
###begin p 56
###xml 12 14 12 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
Kim et al. (17) ascribed the anorexic action of C75 to its ability to inhibit hypothalamic AMPK. Like mTOR, AMPK is a fuel sensor that plays a critical role in integrating signals of energy status in the hypothalamus and regulating food intake. However, in contrast to mTOR, hypothalamic AMPK is activated during negative energy balance, in which case it stimulates feeding (34). The relationship between these two fuel sensors is rather complex and appears to be bidirectional (35,36). Given the highly regulated crosstalk between mTOR and AMPK, the current experiments cannot rule out whether the effects of C75 on the mTORC1 pathway are directly mediated or occur as a result of inhibition of hypothalamic AMPK. Nonetheless, the data of Kim et al. (17) suggest that AMPK activity is involved primarily in the short-term actions of C75 because AMPK activators inhibit the effect of C75 specifically during the 1st h after drug administration, whereas our data suggest that mTORC1 signaling might be critical at later time points.
###end p 56
###begin p 57
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 827 828 824 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 906 907 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 979 981 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1195 1196 1192 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1357 1359 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1360 1362 1357 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 1363 1365 1360 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
In conclusion, we provide evidence that links the FAS pathway to the mTORC1 signaling cascade in the CNS and, although the current experimental design does not allow us to conclude whether the ability of FAS inhibition to reduce food intake is due exclusively to actions in the hypothalamus, the literature would argue that it is the case. Several studies have attributed the hypophagic action of FAS inhibition to direct effects on hypothalamic neurons (31,37-40), and this model has been further supported in the recent study of Chakravarthy et al. (40). This group demonstrated that genetic inactivation of FAS in the hypothalamus and beta-cells results in anorexia entirely due to inactivation of the enzyme in the hypothalamus. Moreover, nutritional regulation of mTORC1 signaling occurs specifically in the hypothalamus (4). Taking into account that leptin also activates mTORC1 in the hypothalamus (4) and reduces food intake through actions on CNS fatty acid metabolism (18), this suggests that mTORC1 is an important integrator of multiple signals in the CNS. mTORC1 activity can be found in both agouti-related protein-and proopiomelanocortin-producing neurons in the arcuate nucleus (4), and, thus, increased mTORC1 activity in the CNS may contribute to the similar effects of C75 and leptin on both food intake and hypothalamic gene expression (15,17,41). The current data connect two separate metabolic pathways that have been independently implicated in the CNS regulation of energy balance, thus providing new knowledge on the relationship among key signaling pathways able to affect feeding behavior. Identifying the specific metabolic signals that are integrated by energy-sensing neurons is a crucial scientific question that could give important insights into potential etiologies and therapies for obesity and other metabolic disorders.
###end p 57
###begin title 58
Supplementary Material
###end title 58
###begin title 59
Online-Only Appendix
###end title 59
###begin p 60
R.J.S. and S.C.W. have received National Institutes of Health Grants DK-17844, DK-54890, and DK-056863 and funds from the DoD Biomedical Research Program. K.P. has received a fellowship from Fond de la recherche en sante Quebec (FRSQ4729).
###end p 60
###begin p 61
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 90 93 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 94 98 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
We thank Drs. Sara C. Kozma, Georges Thomas, and Matthias H. Tschop for providing the S6K1-/- mice. We are also grateful to Nancy Doughman for measuring plasma leucine levels and to Emily Matter and Joyce Sorrell for expert technical assistance.
###end p 61
###begin p 62
Part of this study was presented in poster form at the 88th annual meeting of the Endocrine Society, Boston, Massachusetts, 24-27 June 2006.
###end p 62
###begin title 63
REFERENCES
###end title 63
###begin p 64
###xml 140 141 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 146 147 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 227 228 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 238 239 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 243 244 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 255 256 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 134 138 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 281 285 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 339 343 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
C75 increases hypothalamic mTORC1 signaling. Representative Western blots from RPMI-treated or C75-treated (30 mug in 2 mul RPMI icv) rats (A and C) and quantification by image analysis of hypothalamic phosphorylation of S6K1 (B) and S6 (D). *P < 0.05; **P < 0.01 vs. RPMI-treated rats. pS6K1: bands were quantified. Means +/- SE of seven rats in each condition.
###end p 64
###begin p 65
###xml 174 175 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 180 181 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 210 211 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 314 315 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 327 328 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 366 367 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 402 403 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 408 409 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 508 512 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 512 515 506 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 522 523 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 734 735 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 740 741 732 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 788 789 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 794 795 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 799 800 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 811 812 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 824 825 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 870 871 862 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 883 887 875 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 887 890 879 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 282 286 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 359 363 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 396 400 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 516 520 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 557 561 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 609 613 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 863 867 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 905 909 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
mTORC1 signaling contributes to the anorexic effect of C75. Rapamycin (RAPA; 25 mug in 1 mul DMSO icv) prevents the effects of C75 (50 mug in 3 mul RPMI icv) on food intake (A and B) and on body weight change (C). Data are the mean of two separate experiments. Means +/- SE of 9-15 rats in each treatment group. **P < 0.01; ***P < 0.001 vs. DMSO/RPMI-treated rats; #P < 0.05 vs. RAPA/C75-treated rats. D and E: The anorexic effect of C75 (20 mg/kg, in 1 ml/100 g body wt RPMI ip) is significantly reduced in S6K1-/- mice. F: Body weight change over 24 h in mice injected with RPMI or C75. Means +/- SE of six mice in each treatment group. Food intake is expressed as the noncumulative amount consumed during different time intervals (A and D) and the cumulative amount eaten during 24 h (B and E). *P < 0.05; **P < 0.01; ***P < 0.001 vs. wild-type (RPMI)-treated mice; #P < 0.05 vs. S6K1-/- (C75)-treated mice.
###end p 65
###begin p 66
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 110 111 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 298 299 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 311 312 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 426 427 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 432 433 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 528 532 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 532 535 528 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 542 543 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 755 756 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 803 804 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 808 809 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 820 821 814 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 833 834 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 897 898 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 910 914 904 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S6K1</italic>
###xml 914 917 908 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 207 211 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 337 341 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 402 406 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 536 540 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 577 581 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 630 634 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 859 863 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 931 935 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Cerulenin activates hypothalamic mTORC1 signaling, and this effect is required for its anorexic action. A and B: Representative Western blots from VEH-treated or CERU-treated (90 mug in 2 mul RPMI-DMSO icv) rats and quantification by image analysis of hypothalamic phosphorylation of S6K1 and S6. *P < 0.05; ***P < 0.001 vs. VEH-treated rats. pS6K1: bands were quantified. Mean +/- SE of five to seven rats in each condition. C and D: The anorexic effect of CERU (160 mg/kg in 1 ml/100 g body wt ip) is significantly reduced in S6K1-/- mice. E: Body weight change over 24 h in mice injected with VEH or CERU. Mean +/- SE of eight mice in each treatment group. Food intake is expressed as the noncumulative amount consumed during different time intervals (C) and the cumulative amount eaten during 24 h (D). *P < 0.05, **P < 0.01; ***P < 0.001 vs. VEH-treated mice of the corresponding genotype; ##P < 0.01 vs. S6K1-/- CERU-treated mice. WT, wildtype.
###end p 66
###begin p 67
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 401 402 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 444 445 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 553 554 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 717 718 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 898 899 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 978 979 965 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1105 1106 1092 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1111 1112 1098 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1192 1193 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1203 1204 1190 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1208 1209 1195 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1224 1225 1211 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1281 1282 1268 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 94 98 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 103 107 <span type="species:ncbi:10118|species:ncbi:10116">Rats</span>
###xml 368 372 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 415 419 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 523 527 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 621 625 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 743 747 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 799 803 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 892 896 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 955 959 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 972 976 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1051 1055 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1251 1255 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1306 1310 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
The actions of C75 on food intake and on hypothalamic mTORC1 signaling are blunted in ketotic rats. A: Rats maintained on a ketogenic diet for 4 weeks while receiving a drinking solution of saccharin have elevated blood beta-hydroxybutyrate concentration compared with those that consumed a solution of sucrose in addition to the ketogenic diet. Means +/- SE of 17-18 rats in each treatment group. ***P < 0.001 vs. rats from the sucrose group. E: Both groups had similar plasma leucine levels. Means +/- SE of six to seven rats in each treatment group. B: C75 (30 mug in 2 mul RPMI icv) does not reduce caloric intake in rats given access to saccharin alongside with the ketogenic diet, but it does so with sucrose. *P < 0.05 vs. RPMI-treated rats from the same group. Means +/- SE of five to eight rats in each treatment group. C75 (30 mug in 2 mul RPMI icv) increased pS6K1 only in sucrose rats (C) and was less efficient at increasing pS6 in saccharin rats vs. sucrose rats (D). Two independent Western blots representative of RPMI- or C75-treated rats either from the sucrose or the saccharin groups (C and D) and quantification by image analysis of hypothalamic phosphorylation of S6K1 (C) and S6 (D). *P < 0.05 and ***P < 0.001 vs. RPMI-treated rats from the same group and #P < 0.05 vs. C75-treated rats from the sucrose group. Means +/- SE of five to nine brains examined in each condition.
###end p 67

